72 h of treatment with MEK1/2 inhibitor decreases the cell viability of all melanoma cells in a dose-dependent manner, with the V600EBRAF positive cells (Mel28 and DFB) being slightly more sensitive, each with an IC50 of around 20 μM (Figure 1B). Here, MAP2K1 is linked to melanoma.